Slide 1: Interim Data for KYSA-6 Phase 2 Clinical Trial of KYV-101 in Generalized Myasthenia Gravis
Interim Data for KYSA-6 Phase 2 Clinical Trial of KYV-101 in Generalized Myasthenia Gravis Conference Call October 29, 2025 Cindy MG Warrior
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements This presentation contains forward-looking statements that are based on management’s beliefs and assumptions and information currently available to management of Kyverna Therapeutics, Inc. (“Kyverna”, “we”, “our,” or the “Company”). All statements other than
Slide 3: Introduction
Introduction Warner Biddle – Chief Executive Officer
Slide 4: Today's Agenda
Today’s Agenda Speakers • Introduction • Interim Phase 2 gMG Data Results Warner Biddle Naji Gehchan M.D., MSc, MBA Chief Executive Officer Chief Medical • Neuroimmunology Franchise & Development Officer and Future Growth Q&A Opportunities • Q&A Marc Grasso M.D. Sri Muppidi M.D. Chief Financial Offi
Slide 5: Despite Available Treatment Options, High Disease Burden Remains in Generalized Myasthenia Gravis (gMG)
Despite Available Treatment Options, High Disease Burden Remains in Generalized Myasthenia Gravis (gMG) • MG is a B-cell and antibody-mediated Current State of Treatment neuromuscular autoimmune disease for Patients With gMG that causes fluctuating muscle weakness and fatigue1,2 Inadequate symptom c
Slide 6: KYV-101: Upstream Targeting at the Disease Source
KYV-101: Upstream Targeting at the Disease Source – A Fundamentally Different Approach to Treating gMG KYV-101 deeply depletes Disease Source in B cells including in tissues1 Lymphoid Tissues Lymph node Upstream B cells B-cell targeting mAbs cannot fully penetrate tissues and primarily target <1% of
Slide 7: KYV-101: Unique CAR Designed for Potency & Tolerability in Autoimmune Diseases
KYV-101: Unique CAR Designed for Potency & Tolerability in Autoimmune Diseases Fully Human Autologous CD19 CAR T With CD28 Costim KYV-101 CAR Construct1,2 • More than 100 patients dosed with KYV-101 across multiple indications; no high-grade CRS or ICANS have been Anti-CD19 scFv observed3 • KYV-101
Slide 8: Compelling Phase 2 Results Reinforce KYV-101's Potential to Change the Treatment Paradigm in gMG
Compelling Phase 2 Results Reinforce KYV-101’s Potential to Change the Treatment Paradigm in gMG Only KYV-101 Has the Potential to Deliver ALL Four Components of a Paradigm-Shifting Therapy 1. 2. 3.Opportunity to 4. Single-Dose Unprecedented More Patients to Disease Control + Minimal Symptom Remove
Slide 9: Changing the Treatment Paradigm in gMG
Changing the Treatment Paradigm in gMG Naji Gehchan, MD, MSc, MBA – Chief Medical and Development Officer
Slide 10: KYSA-6: Phase 2/3 Study of KYV-101 in gMG
KYSA-6: Phase 2/3 Study of KYV-101 in gMG Phase 2 design: Open-label, single-arm, multicenter study N=6 • Age 18 to 75 years • Diagnosis of gMG, Class IIB-IV per MGFA criteria KYV-101 Primary endpoints • Autoantibodies to AChR, • MG-ADL at 24 weeks 18-month MuSK, or LRP4 Cy/Flu lymphodepletion • Adv
Slide 11: Patients Treated With KYV-101 Had Moderate to Severe gMG
Patients Treated With KYV-101 Had Moderate to Severe gMG Characteristic N=6 Age, mean years (range) 45.5 (21-62) • All patients had robust Sex, female | male, n (%) 5 (83%) | 1 (17%) Duration of MG, mean years (range) 5.3 (1.7-13.3) CAR T-cell expansion and Total outcome score, mean (range) B-cell d
Slide 12: KYV-101 Demonstrated Rapid, Robust, and Sustained Reductions in MG-ADL and QMG
KYV-101 Demonstrated Rapid, Robust, and Sustained Reductions in MG-ADL and QMG MG-ADL score QMG score Change from BL Change from BL Baseline Baseline Week 2 Week 24 20 Week 2 Week 24 12 Mean MG-ADL 11.2 -7.8 -8.0 Mean QMG 17.3 -7.8 -7.7 Mean Baseline MG-ADL Mean Baseline QMG 15 Mean Total QMG Score
Slide 13: Substantial and Clinically Meaningful Reductions in MG Outcome Scores and Treatment Burden
After a Single Dose of KYV-101, Patients Achieved Substantial and Clinically Meaningful Reductions in MG Outcome Scores and Treatment Burden Substantially Improved MG-ADL, QMG, and MGC • 100% clinically meaningful response by MG-ADL & QMG (Reduction of ≥2 by MG-ADL, ≥3 by QMG) • 100% responders by M
Slide 14: KYV-101 was Well-Tolerated with No High-Grade CRS and No ICANS Observed
KYV-101 was Well-Tolerated with No High-Grade CRS and No ICANS Observed Safety Patients (n=6) • No ICANS observed • CRS was low-grade and manageable in all CRS (any Grade), n (%) 6 (100) patients Grade 1 4 (67) − 4 of 6 patients only experienced fever (Grade 1 Grade 2 2 (33) CRS) ICANS (any Grade),
Slide 15: Well-Positioned to Achieve Best-in-Class Results in gMG with Phase 3 Trial
Well-Positioned to Achieve Best-in-Class Results in gMG with Phase 3 Trial In 6 patients with moderate to severe gMG, a single dose of KYV-101 resulted in: Robust, rapid, and sustained improvements regardless of prior biologic exposure – Reduction of MG disease scores at 24 weeks: -8.0 for MG-ADL an
Slide 16: Robust Phase 2 Results Strengthen Confidence in Phase 3 Powering Assumptions
Robust Phase 2 Results Strengthen Confidence in Phase 3 Powering Assumptions, Efficient Trial-Size, and Co-primary Endpoint Measurement Reductions in MG-ADL and Deep, sustained treatment QMG exceeded the effect was observed at magnitude of effect week 24 - the timepoint of assumed for Phase 3 assess
Slide 17: Innovative and FDA-Aligned Registrational Phase 3 Trial Design
Innovative and FDA-Aligned Registrational Phase 3 Trial Design ~60-patient, global, open-label, randomized controlled Phase 2/3 trial with crossover design Co-Primary Endpoints (MG-ADL & QMG) KYV-101 Screening, Cy/Flu lymphodepletion + N = ~60 Single infusion of 1×108 CAR T cells Follow Up washout,
Slide 18: Unprecedented MG Clinical Outcome Measures Achieved with a Single Dose of KYV-101
Unprecedented MG Clinical Outcome Measures Achieved with a Single Dose of KYV-101 Approved Investigational* FcRn Complement CD19 BCMA mRNA KYV-101 Inhibitor1 Inhibitor2,3 mAb4,5 CAR T6 CD19 CAR T VYVGART® ULTOMIRIS® UPLIZNA® Descartes-08 (KYSA-6, n=3) Primary Endpoint 4 weeks 6 months 6 months 3 mon
Slide 19: Accelerating Potential First-in-Class CAR T Franchise with MG and SPS
Accelerating Potential First-in-Class CAR T Franchise with MG and SPS Warner Biddle – Chief Executive Officer
Slide 20: Potential to Change the Treatment Paradigm in a Large and Growing Market with KYV-101
Potential to Change the Treatment Paradigm in a Large and Growing Market with KYV-101 KYV-101 Addressable Market1,3 ~80k Initial Total KYV-101 Priority Addressable Market U.S. Diagnosed gMG Patients1,2 ~12k Patients ~40k Patients 15% of total diagnosed 50% of total diagnosed Patients with inadequate
Slide 21: Robust Market Opportunity Supported by Efficient and Scalable Commercial Strategy
Robust Market Opportunity Supported by Efficient and Scalable Commercial Strategy in Neuroimmunology Neuroimmunology Franchise Synergies Treatment Physicians Rapid market entry and uptake in Centers MG to be supported by first- mover advantage in stiff person MG syndrome (SPS) and neuroimmunology fr
Slide 22: Our Focus and Strong Execution Position Kyverna for Future Growth
Our Focus and Strong Execution Position Kyverna for Future Growth NEUROIMMUNOLOGY BROADER PIPELINE Accelerating potential first-in-class CAR T Strategically pursuing expansive franchise, beginning with MG and SPS opportunity in autoimmune disease MG: Clear path to BLA with FDA-aligned MS and RA: Pro
Slide 23: Multiple, Value-Creating Near-Term Catalysts
Multiple, Value-Creating Near-Term Catalysts Program Anticipated Milestones Complete Pivotal Phase 2 Enrollment mid-2025 Stiff Person Syndrome Report Topline Pivotal Phase 2 Data 1H 2026 RMAT, ODD BLA filing in 1H 2026 Confirm Registrational Path with Regulators 1H 2025 Myasthenia Gravis Reported Po
Slide 24: Q&A
Q&A
Slide 25: Key Takeaways from Today
Key Takeaways from Today 1 Kyverna is uniquely positioned to fundamentally change the treatment paradigm in gMG Data reinforces KYV-101’s potential to deliver durable, drug-free, disease-free remission with a single dose 2 Today’s unprecedented clinical trial results increase confidence in Kyverna’s